FSUE "Moscow Endocrine Plant" (Endopharm) has launched the production of the first veterinary drug in its range. The first batch has already been brought to the Russian market. This was told by Vladislav Ovchinsky, head of the Department of Investment and Industrial Policy of Moscow, which is part of the Complex of Economic Policy and Property and Land Relations of the capital, the press service of DIiPP reported.
The drug is used as part of complex therapy for dogs and cats as an analgesic for moderate and severe pain syndrome in the postoperative period, for injuries, diagnostic or therapeutic manipulations, including dental, and other non-infectious diseases accompanied by pain syndrome.
FSUE "Moscow Endocrine Plant" is under the jurisdiction of the Ministry of Industry and Trade of the Russian Federation and is one of the key manufacturers of vital and socially significant medicines in the country.
Endopharm consists of four4 production sites, its own scientific and pharmaceutical development departments, a vivarium, an accredited testing laboratory and more than 1.8 thousand specialists.
